Congress in Spain were a major feature of research news last week, including those from Pfizer on it ponsegromab in cancer ...

Japan's MHLW has accepted for review GSK's NDA for Blenrep for patients with relapsed or refractory multiple myeloma.

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company's product portfolio includes prescription medicines and ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

Nigeria’s pharmaceutical companies are ramping up investments and expanding operations to tap growing local opportunities.

Until recently, the pharmaceutical industry remained relatively insulated from the simmering trade war between China and the ...

Shares in iTeos Therapeutics dropped over 20% despite positive interim data from the GALAXIES Lung-201 Phase II study with ...

China’s NMPA granted BTD for Blenrep (belantamab mafodotin) combined with BorDex for the treatment of multiple myeloma.

The London-based pharmaceutical company said Japan's Ministry of Health, Labour and Welfare has accepted the application to review its Blenrep antibody drug in combination with BorDex or PomDex as a ...

Anervea.ai, a global leader in AI-powered commercialization solutions for the Pharmaceutical, Life Sciences, and Biotech ...

This Fool wants to make the most of the benefits a Stocks and Shares ISA provides. He's keen on these two stocks. The post I ...